Notice of Privacy Practices
Last Updated: 08/20/2026
This notice describes how medical information about you may be used and disclosed and how you can access this information.
Our Responsibilities
PLEXUSDX, INC. is required by law to maintain the privacy and security of your Protected Health Information (PHI).
We must provide you with this notice describing our legal duties and privacy practices.
Uses and Disclosures of Health Information
Your health information may be used for:
Treatment
Sharing information with healthcare providers involved in your care.
Payment
Processing payments for healthcare services.
Healthcare Operations
Administrative activities including quality improvement and service management.
Your Rights
You have the right to:
- Access your health records
- Request corrections to your records
- Request confidential communications
- Request restrictions on certain disclosures
-
Receive a copy of this notice
Complaints
If you believe your privacy rights have been violated, you may file a complaint with:
Jason Hastings
CEO, PlexusDx Inc.
support@plexusdx.com
You may also file a complaint with the U.S. Department of Health and Human Services.
Contact Information
PLEXUSDX, INC.
6110 McFarland Station Drive, #604
Alpharetta, GA 30004
info@plexusdx.com
877-760-2333
Important information
Compounded medications are not approved by the FDA or reviewed for quality, safety, or efficacy.
Novo Nordisk, Inc. is the only United States company with FDA-approved products containing semaglutide, identified under the trade names Rybelsus®, Ozempic®, and Wegovy®.
Lilly USA LLC is the only United States company with FDA-approved products containing tirzepatide, identified under the trade names Zepbound® and Mounjaro®.
The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.